In 2022, Takamochi et al. found a clinical association of PD-L2-positive lung adenocarcinoma (LUAD) with biologically aggressive characteristics based on PD-L2 expression status from 980 surgically resected LUAD specimens [57]. The gene discussed is PDCD1LG2; the disease is lung adenocarcinoma.